| Identification | Back Directory | [Name]
Adropin (34-76) (human, mouse, rat) | [CAS]
1802086-30-1 | [Synonyms]
Adropin (34-76) (human, mouse, rat)
H-Cys-His-Ser-Arg-Ser-Ala-Asp-Val-Asp-Ser-Leu-Ser-Glu-Ser-Ser-Pro-Asn-Ser-Ser-Pro-Gly-Pro-Cys-Pro-Glu-Lys-Ala-Pro-Pro-Pro-Gln-Lys-Pro-Ser-His-Glu-Gly-Ser-Tyr-Leu-Leu-Gln-Pro-OH |
| Hazard Information | Back Directory | [Uses]
Adropin (34-76) is a secretory domain of Adropin. Adropin (34-76) can inhibit cAMP level and glucose production in hepatocytes, and has a hypoglycemic effect. Adropin (34-76) plays an antifibrotic role by inhibiting the GLI1 signaling pathway[1][2]. | [in vivo]
Adropin (34-76) (450 nmol/kg ≈ 2 mg/kg; intraperitoneal injection; 5 injections within 48 hours) has a hypoglycemic effect in a diet-induced obesity model of mice[1].
Adropin (34-76) (10 μg/kg/h; subcutaneous osmotic pump; 25 days) has an improved effect in the mouse model of fibrosis[2]. | Animal Model: | Male DIO B6 mice[1] | | Dosage: | 450 nmol/kg ≈ 2 mg/kg | | Administration: | Five intraperitoneal injections over a 48-h period | | Result: | Enhanced intracellular signaling actions underlying insulin’s effect on hepatic glucose metabolism.
Alleviated hepatic ER stress responses.
Diminished JNK and PKA signaling in the liver.
Down-regulates hepatic lipogenic genes.
Altered the phosphorylation levels of IP3R in the liver.
|
| Animal Model: | Mouse with fibrosis model[2] | | Dosage: | 10 μg/kg/h | | Administration: | Subcutaneous osmotic pump; 25 days | | Result: | Ameliorated allogeneic bone marrow transplantation (alloBMT)-induced skin fibrosis, with reduced dermal thickness, lower myofibroblast counts, and decreased hydroxyproline content.
Ameliorated alloBMT-induced pulmonary fibrosis, with reduced Ashcroft scores and hydroxyproline content.
|
| [References]
[1] Gao S, et al. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 2019 Sep 6;294(36):13366-13377. DOI:10.1074/jbc.RA119.008967
[2] Liang M, et al. Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis. Sci Transl Med. 2024 Mar 27;16(740):eadd6570. DOI:10.1126/scitranslmed.add6570 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|